Biotech Sector Faces Hurdles After an Explosive Year

The biotechnology sector is facing headwinds entering 2022, after an explosive year for funding and initial public offerings.

Biotech companies rolled into 2021 with momentum stemming from innovation in the industry and its role in combating the Covid-19 pandemic. Stock prices surged early in the year and startups leapt onto the public markets.

Get the week’s top news delivered directly to your inbox – Sign up for our newsletter

Sign up

The investment world saw a great amount of deals within the biotech space.

Biotechnology company Senti Biosciences has agreed to go public through a merger with blank-check firm Dynamics Special Purpose Corp in a deal that values the combined company at $601 million.

Jeito Capital, a rapidly growing, new, independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at $630m, exceeding its original target of €500m. Jeito I is the largest European fund dedicated to supporting companies in the life sciences sector.

Ginkgo Bioworks reavealed plans to go public through a merger with a blank-check vehicle backed by former Hollywood executives Harry Sloan and Jeff Sagansky from Eagle Equity Partners, in one of the biggest such deals that values the biotech company at $17.5bn.

Source: Wall Street Journal

Can’t stop reading? Read more